Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes

Drug Metabolism and Disposition

Volumn 34, Issue 11, 2006, Pages 1798-1802

  Bu, Hai Zhi ^a   Zhao, Ping ^a,b   Kang, Ping ^a   Pool, William F ^a   Wu, Ellen Y ^a  

^a PFIZER INC   (United States)

^b Sonus Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPRAVIRINE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DRUG METABOLITE; QUERCETIN; RITONAVIR; SULFAPHENAZOLE; TICLOPIDINE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; LIVER MICROSOME; OXYGENATION; PRIORITY JOURNAL;

ANTI-HIV AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; IMIDAZOLES; MICROSOMES, LIVER; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; SULFUR COMPOUNDS;

TETRA;

EID: 33751097278     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.011189     Document Type: Article

References (13)

1. Back DJ, Tjia JF, Karbwang J, and Colbert J (1988) In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides, and quinolines. Br J Clin Pharmacol 26:23-29.
2. Bu H-Z, Kang P, Zhao P, Pool WF, and Wu EY (2005) A simple sequential incubation method for deconvoluting the complicated sequential metabolism of capravirine in humans. Drug Metab Dispos 33:1438-1445.
3. Bu H-Z, Pool WF, Wu EY, Raber SR, Amantea MA, and Shetty BV (2004) Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab Dispos 32:689-698.
4. De Clercq E (2001) New developments in anti-HIV chemotherapy. Curr Med Chem 8:1543-1572.
5. De Clercq E (2002) Highlights in the development of new antiviral agents. Mini Rev Med Chem 2:163-175.
6. Donahue SR, Flockhart DA, Abernethy DR, and Ko JW (1997) Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacol Ther 62:572-577.
7. Hodgson E and Goldstein JA (2001) Metabolism of toxicants: phase I reactions and pharmacogenetics, in Introduction to Biochemical Toxicology, 3rd ed (Hodgson E and Smart RC eds) pp 67-112, John Wiley & Sons Inc., New York.
8. Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, and Granneman GR (1999) Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab Dispos 27:902-908.
9. Lawton MP, Cashman JR, Cresteil T, Dolphin CT, Elfarra AA, Hines RN, Hodgson E, Kimura T, Ozols J, Phillips IR, et al. (1994) A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities. Arch Biochem Biophys 308:254-257.
10. Marill J, Capron CC, Idres N, and Chabot GG (2002) Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids. Biochem Pharmacol 63:933-943.
11. Overby LH, Buckpitt AR, Lawton MP, Atta-Asafo-Adjei E, Schulze J, and Philpot RM (1995) Characterization of flavin-containing monooxygenase 5 (FMO5) cloned from human and guinea pig: evidence that the unique catalytic properties of FMO5 are not confined to the rabbit ortholog. Arch Biochem Biophys 317:275-284.
12. Phillips IR, Dolphin CT, Clair P, Hadley MR, Hutt AJ, McCombie RR, Smith RL, and Shephard EA (1995) The molecular biology of the flavin-containing monooxygenases of man. ChemBiol Interact 96:17-32.
13. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, and Shader RI (1998) Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 38:106-111.